Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Kabi is a fluoroquinolone antibiotic used to treat bacterial infections in various organ systems.

• Community‑acquired bacterial pneumonia: effective bacterial eradication leading to clinical recovery.
• Complicated intra‑abdominal infections: helps resolve infection after surgical source control.
• Complicated skin and skin‑structure infections: reduces bacterial load and promotes healing.
• Acute bacterial sinusitis: alleviates symptoms by eliminating causative pathogens.

• Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By binding to these targets, it prevents bacterial DNA supercoiling and separation, leading to halted cell division and bacterial cell death. This bactericidal action is effective against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Rash: skin erythema or mild pruritus.
• Elevated liver enzymes: transient increases in hepatic transaminases.
• Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles tendon.
• QT interval prolongation: risk of cardiac arrhythmias, particularly torsades de pointes.
• Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm.
• Clostridioides difficile infection: severe colitis following disruption of gut flora.
• Hepatic failure: rare but potentially life‑threatening liver injury.
• Anaphylactic shock: immediate hypersensitivity requiring emergency care.

Before initiating therapy with Moxifloxacin, consider the following precautions.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic disease: use with caution; monitor liver enzymes regularly.
• Concomitant QT‑prolonging drugs: avoid combined use to reduce arrhythmia risk.
• History of tendon disorders: discontinue if tendon pain or inflammation occurs.
• Pregnancy and lactation: use only if potential benefits outweigh risks.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several medications, requiring careful management.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: increased risk of toxicity.
• Concurrent use of QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk.
• Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect; monitor INR closely.
• Corticosteroids: increased risk of tendon rupture; assess patient symptoms regularly.